You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Eigen Health Services LLC Topic: 102
Project Summary Prostate cancer is one of the most commonly occurring forms of cancer, accounting for 21% of all cancer in men. The Prostate Imaging Reporting and Data System (PI-RADS) aims to standardize reporting of prostate cancer using multi-parametric magnetic resonance imaging (mpMRI). However, the in-depth analysis, as demanded by PI-RADS, remains challenging due to the complexity and heter ...STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Circumvent Pharmaceuticals Topic: NICHD
SummaryIn the Specific Aims outlined by the following proposal for an NIH SBIR Phase 1 project, we will use a multi-faceted approach to identify key substrates for targeted assay development to monitor therapy in for CLN1 Batten Disease (CLN1). CLN1 is an ultra-rare neurodegenerative disease that affects children with autosomal recessive mutations in the gene for palmitoyl-protein thioesterase 1 ( ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
Multi-Modality Image Data Fusion and Machine Learning Approaches for Personalized Diagnostics and Prognostics of MCI due to ADSBC: MS Technologies Corporation Topic: R
Alzheimer’s Disease (AD) is a devastating neurodegenerative disease. The greatest treatment potential lies in early stages before irreversible brain damage occurs. Early treatment requires early detection of the disease. Imaging holds great promise for capturing early signs of AD. This capability can be substantially strengthened by integrating neuroimages of different modalities that characteri ...STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: ELECTRONIC BIOSCIENCES, INC. Topic: 172
Project Summary During this project, Electronic BioSicences (EBS) and Professor Meni Wanunu (at Northeastern University) will develop a true single-molecule, direct, long-lived, RNA sequencer. The developed RNA sequencer will be capable of sequencing RNA with high-accuracy (andgt;99%), as well as iteratively sequencing various samples and quantitatively profiling the RNA content of a given sample, ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
A novel, hand-held, exhaled breath condensate sampler for the clinical research market; applications for asthma, pulmonary injury and inflammation.SBC: SENSIT VENTURES, INC. Topic: NIEHS
ABSTRACTExhaled breath is one of the most non-invasive human effluents that can be captured and analyzed, and yet it has minimal presence as a common clinical endpoint measurement in any branch of modern medicine. There has been a persistent technology gap for both breath sampling and breath analysis, despite the many vulnerable patient populations and age groups that could be aided by its use. Ex ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: NEI
PROJECT SUMMARY Diabetic retinopathy (DR) is a neurovascular complication of diabetes mellitus and the leading cause of blindness in working age adults and elderly, affecting approximately 4.2 million diabetes patients in the US, of which 655,000 have vision-threatening DR. There is an urgent need for the development of additional approaches to prevent and treat diabetic retinopathy, as the curren ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
AlgenML: Drug target discovery platform for transcriptional reprogramming of MYCN-driven neuroblastomaSBC: Algen Biotechnologies Inc Topic: 400
AlgenML: Drug target discovery platform for transcriptional reprogramming of MYCN-driven neuroblastoma PROJECT SUMMARY Drug discovery is a laborious, time-consuming, and expensive undertaking for biopharma. Oncology is especially difficult with new drugs in clinical trials having just 3.4% probability of success. This application addresses significant challenges of traditional drug target discover ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: PATHMAKER MOBILITY CORP. Topic: 109
PROJECT SUMMARY / ABSTRACT Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the spinal cord and brain. ALS causes muscle weakness and paralysis and eventually death. According to the ALS Association, every 90 minutes there is a new diagnosis of ALS, as well as an associated death. Nearly 5,000 people are diagnosed with ALS each year and a ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: POINT DESIGNS, LLC Topic: NIBIB
Multi-Modal Fingertip Sensors for Prosthetic HandControl and FeedbackPROJECT SUMMARY / ABSTRACT The goal of the proposed project is to develop a robust, multi-modal prosthetic fingertip sensor – the Point Touch – which 1) has a patented multi-modal sensing capability including measurement of proximity, contact, and force and 2) can augment myoelectric control methods using semi-autonomous cont ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: ODMR Technologies, Inc Topic: 400
Project Summary. Nuclear magnetic resonance (NMR) is among the most powerful analytical techniques ever invented, as recognized by 6 Nobel Prizes for methods development alone. Nonetheless, NMR is notoriously plagued by poor sensitivity. State-of-the-art NMR spectrometers feature detection thresholds of ~1 nanomole for µL sample volumes (~100 nanograms). This places NMR sensitivity many orders of ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health